Amer Bio Medica
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rap… Read more
Amer Bio Medica (ABMC) - Net Assets
Latest net assets as of March 2023: $-458.00K USD
Based on the latest financial reports, Amer Bio Medica (ABMC) has net assets worth $-458.00K USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($659.00K) and total liabilities ($1.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-458.00K |
| % of Total Assets | -69.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -274.81% |
| Growth Volatility | 34.38 |
Amer Bio Medica - Net Assets Trend (1996–2022)
This chart illustrates how Amer Bio Medica's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amer Bio Medica (1996–2022)
The table below shows the annual net assets of Amer Bio Medica from 1996 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-2.34 Million | -147.78% |
| 2021-12-31 | $-944.00K | +24.84% |
| 2020-12-31 | $-1.26 Million | -58.99% |
| 2019-12-31 | $-790.00K | -441.10% |
| 2018-12-31 | $-146.00K | -123.43% |
| 2017-12-31 | $623.00K | -39.22% |
| 2016-12-31 | $1.02 Million | +6.66% |
| 2015-12-31 | $961.00K | -0.93% |
| 2014-12-31 | $970.00K | -27.50% |
| 2013-12-31 | $1.34 Million | -1.91% |
| 2012-12-31 | $1.36 Million | -42.45% |
| 2011-12-31 | $2.37 Million | -10.80% |
| 2010-12-31 | $2.66 Million | -21.34% |
| 2009-12-31 | $3.38 Million | -20.67% |
| 2008-12-31 | $4.26 Million | -16.44% |
| 2007-12-31 | $5.10 Million | -15.59% |
| 2006-12-31 | $6.04 Million | +8.72% |
| 2005-12-31 | $5.55 Million | -4.88% |
| 2004-12-31 | $5.84 Million | +22.60% |
| 2003-12-31 | $4.76 Million | +43.43% |
| 2002-12-31 | $3.32 Million | +41.10% |
| 2001-12-31 | $2.35 Million | -26.72% |
| 2000-12-31 | $3.21 Million | +8.01% |
| 1999-12-31 | $2.97 Million | -39.33% |
| 1998-12-31 | $4.90 Million | +31.49% |
| 1997-12-31 | $3.73 Million | 0.00% |
| 1996-12-31 | $3.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amer Bio Medica's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2231600800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $481.00K | % |
| Other Components | $22.40 Million | % |
| Total Equity | $-2.34 Million | 100.00% |
Amer Bio Medica Competitors by Market Cap
The table below lists competitors of Amer Bio Medica ranked by their market capitalization.
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amer Bio Medica's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -944,000 to -2,339,000, a change of -1,395,000.
- Net loss of 1,410,000 reduced equity.
- Other comprehensive income increased equity by 1,000.
- Other factors increased equity by 14,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.41 Million | -60.28% |
| Other Comprehensive Income | $1.00K | +0.04% |
| Other Changes | $14.00K | +0.6% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Amer Bio Medica's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $0.29 | $0.00 | x |
| 1997-12-31 | $0.29 | $0.00 | x |
| 1998-12-31 | $0.41 | $0.00 | x |
| 1999-12-31 | $0.20 | $0.00 | x |
| 2000-12-31 | $0.21 | $0.00 | x |
| 2001-12-31 | $0.11 | $0.00 | x |
| 2002-12-31 | $0.16 | $0.00 | x |
| 2003-12-31 | $0.22 | $0.00 | x |
| 2004-12-31 | $0.27 | $0.00 | x |
| 2005-12-31 | $0.26 | $0.00 | x |
| 2006-12-31 | $0.28 | $0.00 | x |
| 2007-12-31 | $0.23 | $0.00 | x |
| 2008-12-31 | $0.20 | $0.00 | x |
| 2009-12-31 | $0.16 | $0.00 | x |
| 2010-12-31 | $0.12 | $0.00 | x |
| 2011-12-31 | $0.11 | $0.00 | x |
| 2012-12-31 | $0.06 | $0.00 | x |
| 2013-12-31 | $0.06 | $0.00 | x |
| 2014-12-31 | $0.04 | $0.00 | x |
| 2015-12-31 | $0.04 | $0.00 | x |
| 2016-12-31 | $0.04 | $0.00 | x |
| 2017-12-31 | $0.02 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $-0.02 | $0.00 | x |
| 2020-12-31 | $-0.04 | $0.00 | x |
| 2021-12-31 | $-0.02 | $0.00 | x |
| 2022-12-31 | $-0.05 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amer Bio Medica utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -154.44%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-27.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -13.56% | -82.72% | 0.15x | 1.10x | $-877.98K |
| 1997 | -13.56% | -82.72% | 0.15x | 1.10x | $-877.98K |
| 1998 | -89.80% | -200.00% | 0.41x | 1.10x | $-4.89 Million |
| 1999 | -56.88% | -24.03% | 1.59x | 1.49x | $-1.99 Million |
| 2000 | -66.52% | -27.91% | 1.52x | 1.57x | $-2.46 Million |
| 2001 | -90.78% | -27.91% | 1.50x | 2.16x | $-2.37 Million |
| 2002 | 21.66% | 6.97% | 1.83x | 1.70x | $387.00K |
| 2003 | 21.65% | 8.26% | 1.84x | 1.42x | $554.80K |
| 2004 | 4.56% | 2.17% | 1.46x | 1.43x | $-317.80K |
| 2005 | -6.77% | -2.89% | 1.64x | 1.43x | $-931.30K |
| 2006 | 3.25% | 1.42% | 1.53x | 1.49x | $-407.70K |
| 2007 | -19.43% | -7.14% | 1.52x | 1.80x | $-1.50 Million |
| 2008 | -19.96% | -6.72% | 1.39x | 2.15x | $-1.28 Million |
| 2009 | -26.64% | -9.25% | 1.38x | 2.08x | $-1.24 Million |
| 2010 | -28.23% | -7.20% | 1.73x | 2.26x | $-1.02 Million |
| 2011 | -14.56% | -3.72% | 1.65x | 2.38x | $-582.00K |
| 2012 | -81.45% | -11.89% | 1.96x | 3.50x | $-1.25 Million |
| 2013 | -58.89% | -8.86% | 1.79x | 3.71x | $-921.80K |
| 2014 | -50.52% | -6.73% | 1.79x | 4.20x | $-587.00K |
| 2015 | -34.65% | -5.27% | 1.66x | 3.95x | $-429.10K |
| 2016 | -33.66% | -6.15% | 1.66x | 3.29x | $-447.50K |
| 2017 | -87.48% | -11.09% | 1.70x | 4.64x | $-607.30K |
| 2018 | 0.00% | -26.55% | 1.56x | 0.00x | $-1.01 Million |
| 2019 | 0.00% | -18.63% | 1.76x | 0.00x | $-602.00K |
| 2020 | 0.00% | -19.19% | 2.15x | 0.00x | $-670.40K |
| 2021 | 0.00% | -20.87% | 1.18x | 0.00x | $-368.60K |
| 2022 | 0.00% | -154.44% | 0.72x | 0.00x | $-1.18 Million |
Industry Comparison
This section compares Amer Bio Medica's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,015,197,507
- Average return on equity (ROE) among peers: -21.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amer Bio Medica (ABMC) | $-458.00K | -13.56% | N/A | $3.55K |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |